#ACC22 – RCT: Diltiazem did not significantly improve coronary vasomotor dysfunction in angina and nonobstructive coronary arteries.

Efficacy of Diltiazem to improve coronary vasomotor dysfunction in angina and nonobstructive coronary arteries (ANOCA): Results of the EDIT-CMD randomized clinical trial – JACC: Cardiovascular Imaging (link to abstract – $ for full-text)

Commentaries:

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD – TCTMD

EDIT-CMD: Diltiazem Not Effective in Reducing Coronary Vasomotor Dysfunction, Improving Angina or QOL in ANOCA Patients – American College of Cardiology

Commentary on Twitter

#ACC22 #JACCIMG SimPub: In this first performed RCT in pts w/ ANOCA, authors show that 6 weeks therapy w/ #diltiazem didn't substantially improve CVDys, symptoms or #QoL when compared w/ placebo, but did ⬇️ prevalence of epicardial spasm. https://t.co/An8v4JHkl4 #CardioTwitter pic.twitter.com/D0fRG0PewG

— JACC Journals (@JACCJournals) April 2, 2022